Investor Relations

Upcoming Event

Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Jun 30, 2023

Company Overview

Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The Company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD), and Chronic Hepatitis B.

Investor Contact Information

Company

Benitec Biopharma Inc.
3940 Trust Way
Hayward, CA 94545
T: +1 (510) 780-0634

Investor Relations

Irina Koffler
Managing Director, LifeSci Advisors
T: 646-970-4681
ikoffler@lifesciadvisors.com

Transfer Agent

Computershare Investor Services
P.O. Box 505005
Louisville, KY 40233-5005
T: 781-575-3100